(Q48489328)

12 February 2018

title

Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study (English)

1 reference

12 February 2018

0 references

Marco Hassler

1

1 reference

12 February 2018

Michael Micksche

2

1 reference

12 February 2018

Günther Stockhammer

3

1 reference

12 February 2018

Josef Pichler

4

1 reference

12 February 2018

Franz Payer

5

1 reference

12 February 2018

Brigitte Abuja

6

1 reference

12 February 2018

Robert Deinsberger

7

1 reference

12 February 2018

Christine Marosi

8

1 reference

12 February 2018

publication date

1 May 2006

1 reference

12 February 2018

published in

Vienna Clinical Weekly

1 reference

12 February 2018

volume

118

1 reference

12 February 2018

issue

7-8

1 reference

12 February 2018

page(s)

230-238

1 reference

12 February 2018

https://scigraph.springernature.com/pub.10.1007/s00508-006-0576-3

exact match

0 references

cites work

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00508-006-0576-3

PCV chemotherapy for recurrent glioblastoma multiforme.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00508-006-0576-3

How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00508-006-0576-3

Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma

21 January 2018

1 reference

12 December 2020

Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study

1 reference

12 December 2020

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma

1 reference

12 December 2020

First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia

1 reference

12 December 2020

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

12 December 2020

Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

1 reference

12 December 2020

1 reference

12 December 2020

Response and progression in recurrent malignant glioma

1 reference

12 December 2020

Temozolomide in patients with high grade gliomas

1 reference

12 December 2020

Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

The effect of sequential radiochemotherapy in preirradiated malignant gliomas in a phase II study

1 reference

12 December 2020

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

12 December 2020

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

Temozolomide as first-line agent in treating high-grade gliomas: phase II study.

1 reference

12 December 2020

Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial

1 reference

12 December 2020

Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center

1 reference

12 December 2020

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

1 reference

12 December 2020

Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study

1 reference

12 December 2020

Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

10.1007/S00508-006-0576-3

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018